AVENIO ctDNA Expanded Kits

For Research Use Only. Not for use in diagnostic procedures.

AVENIO ctDNA expanded kit

Overview

The AVENIO ctDNA Expanded Kit is a next-generation sequencing (NGS) liquid biopsy assay with a 77 gene panel containing genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers. The Expanded Kit is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC).

 

Features and Benefits of AVENIO ctDNA Expanded Kits

  • Contains genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
  • Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
  • Includes reagents, bioinformatics and software
  • Streamlined, end-to-end workflow from extraction to analysis and reporting in five days

Product Highlights

Accurate detection of all four classes of mutations with high sensitivity and specificity2,3

  • >99% sensitivity for all four classes of mutations
  • >99% positive predictive value (PPV) for indels, fusions and CNVs, and >98% PPV for SNVs

View performance data showing >96 to >99% sensitivity and >98 to >99% PPV for all four classes of mutations using the AVENIO ctDNA Expanded Kit.

AVENIO ctDNA expanded kit metrics
Profiling of a broad array of genes with a single assay kit
  • 77 assay targets in a single panel
AVENIO ctDNA expanded kit gene list
A portfolio of NGS liquid biopsy assays

The AVENIO ctDNA Expanded Kit is one of three assays in the AVENIO ctDNA assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit for guideline-driven tumor profiling or the 197-gene AVENIO ctDNA Surveillance Kit for longitudinal tumor burden monitoring.

To ask a question or to speak to a Roche representative
Contact us

References

  1. National Comprehensive Cancer Network. October 15, 2016
  2. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554 doi:10.1038/nm.3519
  3. Data on file.

Specifications

  • Panel size

    192 kb

  • Sample size

    4 ml of plasma

  • cfDNA input

    10-50 ng

  • Reactions per kit

    16

  • Turn-around time

    5 days from extraction to results

To ask a question or to speak to a Roche representative
Contact us